Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction of Factocel IX 600iu:
Factocel IX 600iu is a clotting factor essential for the coagulation cascade, crucial in stopping bleeding by facilitating the formation of blood clots. Individuals with hemophilia B lack sufficient Factor IX, leading to prolonged bleeding and an increased susceptibility to hemorrhage after injuries.
Uses of Factocel IX 600iu:
Hemophilia B Treatment: Factor IX concentrate is primarily employed to treat and prevent bleeding episodes in individuals with hemophilia B. It aids in replacing the missing or deficient Factor IX, enabling proper blood clotting and controlling bleeding.
Surgical Procedures: Factor IX concentrate is also utilized to manage bleeding during and after surgical procedures in individuals with hemophilia B.
Benefits of Factocel IX 600iu:
Bleeding Control: Factocel IX 600iu helps individuals with hemophilia B control and prevent bleeding episodes, thereby improving their overall quality of life and reducing the risk of severe bleeding and related complications.
Surgical Safety: Administering Factocel IX 600iu before and after surgery ensures a safe surgical experience by reducing the risk of excessive bleeding during the procedure.
Mechanism of Action of Factocel IX 600iu:
Factor IX concentrate is a purified form of human Factor IX. When administered, it supplements or replaces the deficient or dysfunctional Factor IX in individuals with hemophilia B. The mechanism of action involves:
Clot Formation: Factor IX plays a crucial role in the coagulation cascade, acting as a catalyst in the conversion of Factor X to its active form, Factor Xa. Factor Xa then initiates a series of reactions leading to the formation of a stable blood clot at the site of injury.
Restoration of Hemostasis: By providing an adequate amount of Factor IX, the clotting process is restored, allowing for proper hemostasis and preventing uncontrolled bleeding.